| 000 | 01737 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250513102510.0 | ||
| 264 | 0 | _c19970123 | |
| 008 | 199701s 0 0 eng d | ||
| 022 | _a0014-2972 | ||
| 024 | 7 |
_a10.1046/j.1365-2362.1996.1790522.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKatschinski, M | |
| 245 | 0 | 0 |
_aIntestinal phase of human antro-pyloro-duodenal motility: cholinergic and CCK-mediated regulation. _h[electronic resource] |
| 260 |
_bEuropean journal of clinical investigation _cJul 1996 |
||
| 300 |
_a574-83 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAcetylcholine _xphysiology |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAtropine _xpharmacology |
| 650 | 0 | 4 |
_aCholecystokinin _xblood |
| 650 | 0 | 4 |
_aDuodenum _xdrug effects |
| 650 | 0 | 4 |
_aGastrins _xblood |
| 650 | 0 | 4 |
_aGastrointestinal Motility _xdrug effects |
| 650 | 0 | 4 |
_aHormone Antagonists _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMuscarinic Antagonists _xpharmacology |
| 650 | 0 | 4 |
_aPancreatic Polypeptide _xblood |
| 650 | 0 | 4 |
_aProglumide _xanalogs & derivatives |
| 650 | 0 | 4 |
_aPyloric Antrum _xdrug effects |
| 650 | 0 | 4 |
_aPylorus _xdrug effects |
| 650 | 0 | 4 | _aReceptor, Cholecystokinin A |
| 650 | 0 | 4 |
_aReceptors, Cholecystokinin _xantagonists & inhibitors |
| 700 | 1 | _aSchirra, J | |
| 700 | 1 | _aBegliner, C | |
| 700 | 1 | _aLangbein, S | |
| 700 | 1 | _aWank, U | |
| 700 | 1 | _aD'Amato, M | |
| 700 | 1 | _aArnold, R | |
| 773 | 0 |
_tEuropean journal of clinical investigation _gvol. 26 _gno. 7 _gp. 574-83 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1046/j.1365-2362.1996.1790522.x _zAvailable from publisher's website |
| 999 |
_c8857210 _d8857210 |
||